NextFin News - Haleon, the world’s largest standalone consumer healthcare group, reported a slowdown in first-quarter sales growth as an unusually mild winter across the Northern Hemisphere dampened demand for its cold and flu remedies. The maker of Sensodyne toothpaste and Panadol painkillers saw organic revenue grow by 2.2% in the three months ended March 31, 2026, a figure that includes a 2.4% benefit from price increases offset by a 0.2% decline in overall volumes.
The London-listed company estimated that the weak respiratory season shaved approximately 130 basis points off its quarterly growth rate. This seasonal headwind was particularly pronounced in North America, where organic revenue growth slowed to 1.0%. While price hikes of 3.7% helped defend margins in the region, volume and mix fell by 2.7%, reflecting both the lack of sneezing and coughing among consumers and a continued normalization of retailer inventory levels following the supply chain volatility of previous years.
Despite the sluggish start, Haleon Chief Executive Brian McNamara reaffirmed the company’s full-year guidance, which targets organic revenue growth of 3% to 5%. The management’s confidence rests largely on the robust performance of its Oral Health division. Organic revenue in that segment surged 8.3% during the quarter, driven by double-digit growth for the Sensodyne and parodontax brands. In the United States, the launch of new premium products like Sensodyne Clinical Repair allowed the company to grow at four times the broader market rate, according to company filings.
Barclays analyst Iain Simpson, who has maintained an "overweight" rating on the stock, noted that while the respiratory drag was expected, the underlying strength in Oral Health provides a necessary cushion. Simpson’s long-term stance has generally been constructive on Haleon’s ability to leverage its brand power to sustain pricing, though he has previously cautioned that the company remains sensitive to seasonal health trends that are outside of management's control. His view is largely mirrored by the broader sell-side, though some analysts remain wary of the company’s high debt levels and the potential for further volume erosion if price hikes continue to outpace wage growth.
A more cautious perspective comes from the broader market's reaction to the volume decline. While the 0.2% dip is marginal, it marks a continuation of a trend where growth is being fueled almost entirely by price rather than increased consumption. If the next cold and flu season also underperforms, or if consumer elasticity finally snaps in the face of persistent inflation, the 3% to 5% annual target could move toward the lower end of the range. For now, investors appear to be giving the company the benefit of the doubt; Haleon shares were trading at 350.80 pence on the London Stock Exchange on Wednesday, up 0.14% as the market weighed the oral care success against the seasonal respiratory slump.
Explore more exclusive insights at nextfin.ai.
